Ascentage Pharma Loss H1 Revenue Jumps 29%; Advances Olverembatinib And Lisaftoclax Programs

Ascentage Pharma reported H1 2026 interim results showing revenue growth of 29%, but a wider net loss versus the prior period. The combination suggests improving top-line momentum alongside deteriorating profitability, keeping the outlook cautious.

Analysis

Ascentage Pharma reported H1 2026 interim results showing revenue growth of 29%, but a wider net loss versus the prior period. The combination suggests improving top-line momentum alongside deteriorating profitability, keeping the outlook cautious.